Pneumoconiosis Symptoms


Pneumoconiosis Symptoms

In the early stages of pneumoconiosis, symptoms are usually mild and intermittent. Some people do not experience any warning signs until they have sustained several years of damage to their lungs. As pneumoconiosis progresses, however, its symptoms tend to become more frequent and severe. These more advanced symptoms can make it difficult to work, exercise or participate in normal daily activities.

The most common symptoms of pneumoconiosis are coughing, wheezing and shortness of breath. These can be present when exercising or even when at rest. Other symptoms include:

  • A chronic feeling of tightness in the chest
  • An increased production of mucus
  • The development of a blue tint in the lips or fingernails (cyanosis)

People who have pneumoconiosis might also develop other related conditions as a result of existing lung damage or inflammation, such as bronchitis, pulmonary hypertension or emphysema. These conditions can cause additional complications that accompany those of pneumoconiosis.

Because pneumoconiosis symptoms can be so disruptive to day-to-day life, finding an effective treatment plan is incredibly important. Many people rely on treatments such as medications, supplemental oxygen and pulmonary rehabilitation to help alleviate their symptoms. Some individuals also consider alternative treatments, such as cellular therapy, to further improve their quality of life.

At the Lung Institute, we provide cellular therapy to help promote the body’s natural healing processes. Our treatments use a patient’s own cells and are performed on an outpatient basis. More than 80 percent of our patients report an improvement in their quality of life after treatment.

If you have been dealing with the symptoms of pneumoconiosis and would like to learn more about cellular therapy as an alternative treatment option, you can contact the Lung Institute at 888-745-6697. Whenever it’s most convenient for you, we’re here to help you Breathe EasierTM.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.